initial public offerings (IPOs) trading on American exchanges

Tuesday, December 17, 2013

Chimerix (CMRX) began trading on the NASDAQ on 8 April 2013


Chimerix, Inc. is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need. Its lipid technology has given rise to two clinical-stage compounds, CMX001 and CMX157, which have demonstrated the potential for enhanced antiviral activity and safety in convenient, orally administered dosing regimens. CMX001 is an orally administered drug that utilizes its lipid technology to deliver intracellular concentrations of a potent antiviral compound, cidofovir-diphosphate (CDV-PP). CMX157, Its second clinical stage compound, is an oral nucleotide compound in Phase 1 development for the treatment of human immunodeficiency virus (HIV) infection.


Suite 340 2505 Meridian Parkway
DURHAM, NC 27713
United States


Key stats and ratios

Net profit margin--13.07%
Operating margin--8.25%
EBITD margin--7.42%
Return on average assets--15.34%
Return on average equity--

No comments:

Post a Comment